Hidradenitis SuppurativaNCT06785675

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

An observational study of Hidradenitis Suppurativa, run by Novartis Pharmaceuticals at 4 sites in United Arab Emirates.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Trial summary

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region. Read more about this study

Who is it for?: Ages 18 to 99 years
Conditions the study is for: Hidradenitis Suppurativa
What is being tested?: Secukinumab
How many people: 53 participants
Where: 4 sitesUnited Arab Emirates
Study dates: 10 Mar 2025to 10 Oct 2026
Phase: Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 99 years
All sexes
No healthy volunteers
Adult, Older adult

Study population: Patients with Hidradenitis Suppurativa who are newly initiated on Secukinumab, across the United Arab Emirates.

Who may be able to join

Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
Male or Female adult patients ≥ 18 years of age at the time of data collection
Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
Agreed to sign an informed consent to be able to fill in the questionnaires.

Who cannot join

Patients not fulfilling any of the abovementioned inclusion criteria.
Patient's refusal to be included in the study or refusal to sign the informed consent.

Trial locations and contacts

4 sites in 1 country.

United Arab Emirates4 sites

Novartis Investigative Site
Abu Dhabi
Novartis Investigative Site
Al Ain Abu Dhabi, United Arab Emirates
Novartis Investigative Site
Ras al-Khaimah
Novartis Investigative Site
Sharjah city

Other trials in United Arab Emirates

About this study

Official title: Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve

Read the detailed description

This is a 24-week longitudinal single-arm prospective study based on data collected from EMRs along with patient-reported outcomes questionnaires (TSQM and DLQI) to evaluate patient-reported satisfaction and early quality of life experiences among HS patients who are newly initiated on Secukinumab. We will be using questionnaires at baseline and at week 24 to report on pre-defined outcomes in a representative HS population across the United Arab Emirates. The data will be collected using an electronic Case Report Form (eCRF) from both data sources (Electronic Medical Report and Questionnaires).

Conditions: Hidradenitis Suppurativa
Being tested: Secukinumab
Medical subject headings: Hidradenitis Suppurativa

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

SecukinumabOther
This is an observational study. There is no treatment allocation.

Study groups in NCT06785675
Study group	Role	What they receive
Secukinumab		Patients who are newly initiated on treatment with Secukinumab Receives: Other: Secukinumab

What is being measured

The primary outcome is the main question the study is designed to answer.

The absolute scores of each of the 4 domains of the Treatment Satisfaction Questionnaire for Medication (TSQM) questionnaire
TSQM scoring is calculated by domain, and each domain score is computed by summing the individual TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100, with higher scores indicating higher patient satisfaction.
4 Domains:
Effectiveness Side Effects Convenience Global Satisfaction
Measured: At Week 24

Secondary outcomes (17)

Change from baseline of the Dermatology Life Quality Index (DLQI) Questionnaire
DLQI is a questionnaire designed to measure the impact of skin conditions on a patient's health-related quality of life. It contains 10 simple, self-administered questions. Focuses on the past week's experiences related to the skin condition. Each question uses a 4-point Likert scale: "Not at all," "A little," "A lot," "Very much."
Measured: Baseline, Week 24
Change from baseline in the Numerical Rating Scale (NRS)
The NRS is commonly used for measuring pain intensity and is well validated. It is scored from 0-10 (0 meaning no pain and 10 meaning the worst pain imaginable).
Measured: Baseline, Week 24
Age (years)
Characteristics of Hidradenitis Suppurativa (HS) patients started on Secukinumab
Measured: Baseline
Gender (male/female)
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Ethnicity
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Weight (kilogram)
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Height (meters)
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Socio-economic status
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Smoking status
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Duration of the disease (time since diagnosis)
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Previous HS-related treatment
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Time since diagnosis to start of the first treatment, and from time since diagnosis to start of Secukinumab
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Hurley Stage
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Number of inflammatory nodules, number of abscesses, and fistulas
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Previous HS-related surgeries
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Previous use of biologic treatment
Characteristics of HS patients started on Secukinumab
Measured: Baseline
Previous and current use of antibiotics treatment
Characteristics of HS patients started on Secukinumab
Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

10 Mar 202510 Oct 2026

First posted21 Jan 2025
Study start10 Mar 2025
Primary completion10 Oct 2026 (estimated)
Study completion10 Oct 2026 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Hidradenitis SuppurativaStudies of the same condition, open and under way.
More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Other
Time perspective: Prospective
Enrolment: 53 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06785675
Sponsor's protocol ID: CAIN457AAE02
Status last verified: Jun 2026
First submitted: 27 Nov 2024
Last updated: 16 Jun 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruitingPhase 2
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Hidradenitis Suppurativa
Not yet recruitingObservational study
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Hidradenitis Suppurativa
Active, not recruitingPhase 2
A Study With CIT-013 in HS Patients
Hidradenitis Suppurativa (HS)
Active, not recruitingPhase 2
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Hidradenitis Suppurativa (HS)
RecruitingPhase 2
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
Hidradenitis Suppurativa (HS)

All Hidradenitis Suppurativa trials